NewAmsterdam’s Obicetrapib Boosts Approval Potential With Positive Combo Data

 
• By Alaric DeArment

The company announced results of the TANDEM study combining the CETP inhibitor with ezetimibe, following successful monotherapy trial data announced in July

hypercholesterolemia
• Source: Shutterstock

More from Clinical Trials

More from Therapy Areas